Afuco™ Anti-CCR2 ADCC Therapeutic Antibody (Plozalizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CCR2. Plozalizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Atherosclerosis, Diabetic nephropathies, Malignant melanoma. It binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-444CQ |
| Pricing | Inquiry |
| Host | Human |
| Target | CCR2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IHC, FC, IP, IF, Inhib |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |